Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 16, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing increases in their personal holdings of Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The material change reported is an increase in share ownership by specific individuals following the re-investment of dividends paid on April 12, 2007. The transactions occurred at a price of GBP 14.23 per Ordinary Share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a regulatory disclosure of shareholding changes in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Important Facts for Investors
- Transaction Type: Increase in Ordinary Share holdings via dividend re-investment.
- Transaction Price: GBP 14.23 per share.
- Dividend Date: April 12, 2007.
- Notified Parties: Mr J S Heslop, Mrs P A Heslop, Mr R Bondy, Mr D Learmouth, Dr D Pulman, Mrs C Pulman, Mr A P Witty, and Mrs C Witty.
- Notification Date: April 16, 2007.